Variant · Snv
PIK3CA D939G
CI-VAR-00000610Explore in graph →NP_006209.2:p.Asp939GlyNM_006218.4:c.2816A>GCIViC 3293
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30205045
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Unmapped disease1unmapped disease | ||||||||
| PIK3CA D939G | (functional) | Functional | D | Supports Gain Of Function | 2 | submitted | EID9176In an analysis of recurrent mutations in breast cancer, the previously unknown PIK3CA D939G mutation was identified. Expression of D939G in MCF10A mammary epithelial cells resulted in increased phosph… (full text at CIViC) PMID 30205045 · Razavi et al., 2018 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available